Arcus Biosciences (RCUS) Net Income towards Common Stockholders (QoQ) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.75% |
| Dec 31, 2025 | 21.48% |
| Mar 31, 2025 | -19.15% |
| Dec 31, 2024 | -2.17% |
| Sep 30, 2024 | 1.08% |
| Jun 30, 2024 | -2,225.00% |
| Mar 31, 2024 | 95.06% |
| Dec 31, 2023 | -14.08% |
| Sep 30, 2023 | 5.33% |
| Jun 30, 2023 | 6.25% |
| Mar 31, 2023 | -19.40% |
| Dec 31, 2022 | -3.08% |
| Sep 30, 2022 | 2.99% |
| Jun 30, 2022 | 1.47% |
| Mar 31, 2022 | -124.33% |
| Dec 31, 2021 | 458.50% |
| Sep 30, 2021 | -2.64% |
| Jun 30, 2021 | -4.65% |
| Mar 31, 2021 | -39.62% |
| Dec 31, 2020 | -2,953.73% |
| Sep 30, 2020 | 104.04% |
| Jun 30, 2020 | -62.41% |
| Mar 31, 2020 | -67.21% |
| Dec 31, 2019 | 24.54% |
| Sep 30, 2019 | 20.53% |
| Jun 30, 2019 | -60.55% |
| Mar 31, 2019 | -43.99% |
| Dec 31, 2018 | -12.67% |
| Sep 30, 2018 | 27.27% |
| Jun 30, 2018 | -14.79% |
| Mar 31, 2018 | 4.62% |
| Dec 31, 2017 | 42.32% |
| Sep 30, 2017 | -139.38% |
| Jun 30, 2017 | -32.38% |